ASCO GI 2023 | Enhancing the efficacy of immune checkpoint inhibitors in CRC

Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, comments on strategies to overcome resistance to immunotherapy in colorectal cancer (CRC). Immunotherapy has made an impact in the current armamentarium as first line therapy or in combination therapy. Novel techniques and tools will enable further understanding of the immunosuppressive nature of the tumor microenvironment, which will lead to novel therapies that can treat cancers refractory to checkpoint inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.